Clinical Trial Update: Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining a combination of NMDA-enhancing and antioxidant treatments for schizophrenia; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: China Medical University Hospital | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING